financetom
Business
financetom
/
Business
/
Allison Transmission Q2 sales beat estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Allison Transmission Q2 sales beat estimates
Aug 4, 2025 2:19 PM

Overview

* Allison Q2 2025 sales beat analyst expectations, driven by Defense market strength

* Diluted EPS hits quarterly record, rising 8% yr/yr

* Co announces acquisition of Dana's Off-Highway business for $2.7 bln

Outlook

* Allison expects 2025 net sales between $3,075 mln and $3,175 mln

* Company anticipates 2025 net income between $640 mln and $680 mln

* Allison projects 2025 adjusted EBITDA between $1,130 mln and $1,180 mln

* Company maintains midpoint of adjusted EBITDA margin guidance

Result Drivers

* DEFENSE MARKET - Net sales increased by $20 mln due to growth initiatives in the Defense end market

* OUTSIDE NORTH AMERICA - Record $142 mln in quarterly net sales driven by higher demand in South America and Europe

* ACQUISITION COSTS - One-time costs related to Dana Off-Highway business acquisition impacted results

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $814 mln $793.70

mln (5

Analysts

)

Q2 EPS $2.29

Q2 Net $195 mln

Income

Q2 Basic $2.32

EPS

Q2 $256 mln

Operatin

g income

Q2 $242 mln

Pretax

Profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the heavy machinery & vehicles peer group is "buy."

* Wall Street's median 12-month price target for Allison Transmission Holdings Inc ( ALSN ) is $105.00, about 16.5% above its August 1 closing price of $87.69

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Firan Technology Secures TSX Approval to Renew Normal Course Issuer Bid
Firan Technology Secures TSX Approval to Renew Normal Course Issuer Bid
Aug 22, 2024
08:17 AM EDT, 08/22/2024 (MT Newswires) -- Firan Technology Group ( FTGFF ) said overnight Wednesday that it secured TSX approval to renew its normal course issuer bid (NCIB) that expired in June. Under the NCIB, the company can purchase up to 1,193,740 of its common shares or 5% of its common shares outstanding as of Aug. 14. Purchases may...
BMW Outpaces Tesla in European EV Sales for First Time
BMW Outpaces Tesla in European EV Sales for First Time
Aug 22, 2024
08:43 AM EDT, 08/22/2024 (MT Newswires) -- BMW AG sold more electric vehicles than Tesla (TSLA) in the European Union for the first time last month, according to data compiled by Jato Dynamics, a consultancy. Sales of fully electric BMWs jumped 35% year over year in July to 14,869, while Tesla recorded a 16% year-over-year decline to 14,561, according to...
NexGold Says Spring Program Shows
NexGold Says Spring Program Shows "Significant" Gold Mineralization, Expands Exploration Programs at Goliath Complex
Aug 22, 2024
08:19 AM EDT, 08/22/2024 (MT Newswires) -- NexGold Mining ( NXGCF ) , which fell 2.9% yesterday, on Thursday said it has begun an expanded exploration program, including soil geochemistry and prospecting and mapping programs at its Goliath Gold Complex in northwestern Ontario. It added the expanded programs will also target the northeast end of the Goldlund claim block, which...
Cognition Therapeutics Reports Positive Results for Alzheimer's Drug in Study
Cognition Therapeutics Reports Positive Results for Alzheimer's Drug in Study
Aug 22, 2024
08:25 AM EDT, 08/22/2024 (MT Newswires) -- Cognition Therapeutics ( CGTX ) said Thursday that its SEQUEL study of its lead Alzheimer's drug candidate CT1812 showed that treated participants exhibited consistent trends of improvement in brain wave patterns and connectivity between brain regions. The study involved 16 participants with mild-to-moderate Alzheimer's. CT1812 was well tolerated, with no severe adverse events...
Copyright 2023-2026 - www.financetom.com All Rights Reserved